PhotoCure ASA (FRA:PHS) Operating Income: €11.23 Mil (TTM As of Mar. 2026)


FRA:PHS PhotoCure ASA FRA:PHS
73 GF Score
Price €5.04
GF Value €6.33
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is PhotoCure ASA Operating Income?

PhotoCure ASA FRA:PHS -2.33% 73 Operating Income is €11.23 Mil as of Mar. 2026. GuruFocus rates FRA:PHS with a GF Score™ of 73/100 and a GF Value™ of €6.33 (Modestly Undervalued). The stock has 1 warning sign investors should review.

PhotoCure ASA's Operating Income for the three months ended in Mar. 2026 was €10.81 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was €11.23 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. PhotoCure ASA's Operating Income for the three months ended in Mar. 2026 was €10.81 Mil. PhotoCure ASA's Revenue for the three months ended in Mar. 2026 was €23.70 Mil. Therefore, PhotoCure ASA's Operating Margin % for the quarter that ended in Mar. 2026 was 45.61%.

PhotoCure ASA's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. PhotoCure ASA's annualized ROC % for the quarter that ended in Mar. 2026 was 74.33%. PhotoCure ASA's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 498.57%.


PhotoCure ASA  (FRA:PHS) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

PhotoCure ASA's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=43.232 * ( 1 - 23.76% )/( (37.138 + 51.549)/ 2 )
=32.9600768/44.3435
=74.33 %

where

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

PhotoCure ASA's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=46.604/( ( (1.134 + max(3.171, 0)) + (1.224 + max(13.166, 0)) )/ 2 )
=46.604/( ( 4.305 + 14.39 )/ 2 )
=46.604/9.3475
=498.57 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(6.33 + 3.749 + 2.002) - (2.738 + 0 + 6.172)
=3.171

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(18.236 + 3.532 + -0.00099999999999767) - (1.589 + 0 + 7.012)
=13.166

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. Operating Income is also linked to Operating Margin %:

PhotoCure ASA's Operating Margin % for the quarter that ended in Mar. 2026 is calculated as:

Operating Margin %=Operating Income (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=10.808/23.698
=45.61 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


PhotoCure ASA Operating Income Related Terms


PhotoCure ASA Operating Income Historical Data

* Premium members only.

The historical data trend for PhotoCure ASA's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PhotoCure ASA Operating Income Chart

PhotoCure ASA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.57 -4.68 2.42 1.74 -0.06

PhotoCure ASA Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.48 0.64 0.25 -0.47 10.81
FRA:PHS
73GF Score
PhotoCure ASA FRA:PHS
Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PhotoCure ASA Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €11.23 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Income →
What does a Operating Income of €11.23 Mil mean?
PhotoCure ASA (FRA:PHS) has a Operating Income of €11.23 Mil as of Mar. 2026. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on PhotoCure ASA and its competitors.
Is PhotoCure ASA's Operating Income too high?
PhotoCure ASA's current Operating Income is €11.23 Mil. Overall, PhotoCure ASA has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PhotoCure ASA's Operating Income compare to ZTS and UTHR?
PhotoCure ASA's Operating Income of €11.23 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Income for a Drug Manufacturers company?
A good Operating Income depends on the Drug Manufacturers industry context. However, Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Income mean?
A high Operating Income can signal that a stock is expensive relative to its fundamentals. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on PhotoCure ASA and its competitors. PhotoCure ASA's current Operating Income is €11.23 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PhotoCure ASA stock overvalued right now?
Based on GuruFocus' analysis, PhotoCure ASA (FRA:PHS) is currently considered Modestly Undervalued. The stock's GF Value™ is €6.33, compared to a current price of €5.04 — trading 20.4% below its estimated fair value. The current Operating Income is €11.23 Mil. PhotoCure ASA's overall GF Score™ is 73/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Income calculated?
Operating Income is calculated from a company's financial statements. For PhotoCure ASA (FRA:PHS), the current Operating Income is €11.23 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PhotoCure ASA (FRA:PHS) Overvalued in 2026?

Based on GuruFocus' analysis, PhotoCure ASA stock appears to be undervalued. The current stock price of €5.04 is trading 20.4% below its estimated GF Value™ of €6.33. GuruFocus considers PhotoCure ASA to be Modestly Undervalued.

Key valuation signals for FRA:PHS:

  • Operating Income: €11.23 Mil
  • GF Value™: €6.33 vs. price of €5.04 (20.4% below fair value)
  • GF Score™: 73/100 with 1 warning sign

No single metric tells the full story. See the FRA:PHS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


PhotoCure ASA Business Description

Address Hoffsveien 4, Oslo, NOR, 0275
PhotoCure ASA is a Norway-based business group associated with the research, development, production, distribution, marketing, and sales of pharmaceutical products and specialty pharmaceutical companies. The technology platform of the company is focused on the field of photodynamic diagnosis and treatment of cancer. The company has two operating segments of the group the Commercial franchise and the Development portfolio. It generates prime revenue from the Commercial franchise segment, which includes Hexvix and Cysview products. Its geographical segments are Nordic countries, Germany, France, Austria, the United Kingdom, BeNeLux, Italy, Other European countries, Canada, and the United States.
73GF Score

Get the complete analysis for FRA:PHS

Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.04
Price
€6.33
GF Value